ストックスクリーナーアプリを入手
2.31
2.74%
-0.06
アフターアワーズ：
2.31
前日終値:
$2.37
開ける：
$2.4
24時間の取引高:
128.24K
Relative Volume:
0.69
時価総額：
$136.98M
収益：
-
当期純損益:
$-64.86M
株価収益率:
-2.0263
EPS:
-1.14
ネットキャッシュフロー:
$-55.66M
1週間 パフォーマンス:
-11.69%
1か月 パフォーマンス:
-14.63%
6か月 パフォーマンス:
-39.50%
1年 パフォーマンス:
-1.50%
1日の値動き範囲:
$2.25
$2.40
1週間の範囲:
$2.23
$2.62
52週間の値動き範囲:
$2.08
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
925-368-8508
住所
427 PARK ST., CHARLOTTESVILLE
ABOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ABOS | 2.31 | 136.98M | 0 | -64.86M | -55.66M | -1.14 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-26 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-20 | 再開されました | BofA Securities | Buy |
| 2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 開始されました | BTIG Research | Buy |
| 2022-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-07-26 | 開始されました | BofA Securities | Neutral |
| 2021-07-26 | 開始されました | Credit Suisse | Outperform |
| 2021-07-26 | 開始されました | Stifel | Buy |
| 2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
HC Wainwright Has Bearish Estimate for ABOS FY2024 Earnings - MarketBeat
Analyzing Ginkgo Bioworks (NYSE:DNA) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 14.2% in October - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given Buy Rating at HC Wainwright - MarketBeat
Earnings call: Acumen Pharmaceuticals reports on Q3 2024 progress - Investing.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic - TipRanks
Acumen Pharmaceuticals' Shares Drop on Wider 3Q Loss - MarketWatch
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Acumen Reports $258.9M Cash Runway Despite Widening Q3 Loss; Alzheimer's Trial Advances | ABOS Stock News - StockTitan
Earnings Scheduled For November 12, 2024 - Benzinga
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at Stifel Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharma announces new appointment | Biotechnology | The Pharmaletter - The Pharma Letter
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference - The Manila Times
Acumen Pharma to Present Alzheimer's Treatment Progress at UBS Healthcare Conference | ABOS Stock News - StockTitan
Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday - MarketBeat
Acumen Pharmaceuticals appoints new regulatory chief - Investing.com
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality - The Manila Times
Acumen Pharma Taps Former Sage Executive to Lead Alzheimer's Drug Development | ABOS Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - WICZ
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference - The Manila Times
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference - StockTitan
Uipath Inc Cl A (PATH-N) QuotePress Release - The Globe and Mail
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Decrease in Short Interest - MarketBeat
National Bank Financial Forecasts TSE:BIP Q3 Earnings - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in October - Defense World
Finance/Insurance: PAUL B. MANNING - Virginia Business Magazine
Acumen reveals Alzheimer's trial screening method By Investing.com - Investing.com Australia
Halozyme to Report Third Quarter 2024 Financial and Operating Results - The Malaysian Reserve
Acumen reveals Alzheimer's trial screening method - Investing.com India
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on - The Bakersfield Californian
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
3 US Penny Stocks With Market Caps Under $500M To Consider - Simply Wall St
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Decreases By 7.7% - MarketBeat
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Millennium Management LLC Has $4.87 Million Position in Exponent, Inc. (NASDAQ:EXPO) - Defense World
Millennium Management LLC Makes New Investment in Super Hi International Holding Ltd. (NASDAQ:HDL) - Defense World
Millennium Management LLC Has $4.88 Million Stock Position in Alamo Group Inc. (NYSE:ALG) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Central Nervous System (CNS) Biomarkers Market Expected - openPR
Renaissance Technologies LLC Acquires Shares of 338,100 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06 - MSN
MGO Private Wealth LLC Buys 9,590 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Sei Investments Co. Makes New $2.49 Million Investment in Plains GP Holdings, L.P. (NYSE:PAGP) - Defense World
Stifel maintains Buy rating on Acumen Pharma shares - Investing.com India
Park National Corp OH Boosts Stake in Vanguard High Dividend Yield ETF (NYSEARCA:VYM) - Defense World
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
Acumen Pharmaceuticals Inc (ABOS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 19 '24 |
Sale |
3.48 |
8,933 |
31,048 |
108,867 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 18 '24 |
Sale |
3.71 |
4,242 |
15,717 |
211,445 |
| Siemers Eric | Chief Medical Officer |
Jan 18 '24 |
Sale |
3.71 |
3,124 |
11,604 |
117,576 |
| Barton Russell | Chief Operating Officer |
Jan 18 '24 |
Sale |
3.73 |
2,833 |
10,555 |
96,867 |
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):